로딩 중…
지수 로딩 중…
L&K Biomed Ltd.
156100· KOSDAQ· Health Care· Health Care Equipment & Services
₩5,790-0.17%
2026-11-02
Financials
Valuation Metrics
L&K Biomed Ltd.'s Market Cap is ₩1294B. At end of 2025 it was ₩2897B. Ranked #1057 of 2,405 in KR market (top 44%), #540 of 1,627 on KOSDAQ (top 33%), #37 of 94 in Health Care Equipment & Services (top 39%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 129.41B KRW | KR#1,057/2,405 Sec#37/94 |
| Revenue | 39.94B KRW | KR#1,905/2,405 Sec#56/94 |
| Net Income | 2.13B KRW | KR#1,401/2,405 Sec#43/94 |
| Total Assets | 109.67B KRW | KR#1,700/2,405 Sec#52/94 |
| Net Assets | 56.54B KRW | KR#1,822/2,405 Sec#57/94 |
| Employees | 81 | KR#1,798/2,405 Sec#70/94 |
| Value | ||
| P/E | 60.89x | KR#1,452/2,405 Sec#47/94 |
| P/B | 2.29x | KR#2,041/2,405 Sec#71/94 |
| PEG | 10.49x | KR#824/2,405 Sec#32/94 |
| P/S | 3.24x | KR#2,031/2,405 Sec#67/94 |
| EV/EBITDA | 292.09x | KR#1,540/2,405 Sec#50/94 |
| FCF Yield | -13.04% | KR—/2,405 Sec—/94 |
| Profitability | ||
| ROE | 3.76% | KR#1,255/2,405 Sec#41/94 |
| ROA | 1.94% | KR#1,230/2,405 Sec#45/94 |
| Op. Margin | 1.30% | KR#1,471/2,405 Sec#50/94 |
| Revenue Growth | -0.11% | KR#1,527/2,405 Sec#74/94 |
| Earnings Growth | 5.81% | KR#779/2,405 Sec#32/94 |
| Financial Health | ||
| Debt Ratio | 93.95% | KR#1,489/2,405 Sec#75/94 |
| Total Debt | 26.97B KRW | KR#1,272/2,405 Sec#33/94 |
| FCF | -16.87B KRW | KR#1,846/2,405 Sec#71/94 |
| Cash | 4.64B KRW | KR#2,022/2,405 Sec#71/94 |
| Current Ratio | 1.89x | KR#917/2,405 Sec#54/94 |
| Net Debt/EBITDA | 42.97x | KR#1,470/2,405 Sec#47/94 |
| Performance | ||
| 1Y Return | -35.88% | KR#1,595/2,405 Sec#54/94 |
| 1M Return | -6.76% | KR#876/2,405 Sec#34/94 |
| From 52W High | -64.70% | KR#1,872/2,405 Sec#70/94 |
| 1Y MDD | -82.41% | KR#2,313/2,405 Sec#89/94 |
| Trading | ||
| Volume | 182,343 shares | KR#407/2,405 Sec#16/94 |
| Trading Value | 1.05B KRW | KR#577/2,405 Sec#14/94 |
| Foreign Own. | 7.16% | KR#623/2,405 Sec#17/94 |
| Per Share | ||
| EPS | 95 KRW | KR#1,433/2,405 Sec#44/94 |
| BPS | 2,530 KRW | KR#1,958/2,405 Sec#63/94 |
Company Info
동사는 2008년 척추 임플란트 개발, 제조, 판매를 시작으로 현재 6개의 비상장 종속회사를 보유하고 있음. 정형외과와 신경외과의 척추고정장치 및 척추 수술용 제품 설계, 개발, 제조, 판매를 주요 사업으로 하고 있으며, 경추용과 흉요추용 제품 라인업을 갖추고 있음. 척추 전문 임플란트 기술 및 연구개발 노하우를 바탕으로 Pectus Bar System 개발을 완료하고 FDA 허가를 받아 흉부임플란트 분야로 확장하고 있음. 엘앤케이바이오는 2008년에 설립되었으며 경기도 용인시에 본사를 두고 있습니다.